Developer docs
API playgroundTry for free, no card

Search company profiles

Deva

Full company profile

uuid000e2b3

Namestring
Deva
Legal namestring
DEVA HOLDİNG ANONİM ŞİRKETİ
Websiteurl
deva.com.tr
Company typeenum
Public
Founded yearint
1958
Descriptiontext

DEVA Holding A.Ş. is a vertically integrated Turkish pharmaceutical manufacturer founded in 1958 and headquartered in Istanbul. The company produces both active pharmaceutical ingredients (APIs) and finished dosage forms across 15 therapeutic areas, including cardiology, oncology, respiratory, hematology, dermatology/immunology, central nervous system, and musculoskeletal segments. Manufacturing is concentrated at four Turkish facilities: Çerkezköy-I (52,000 m²) for liquids, semi-solids, cephalosporins, penicillins, hormones, inhalation products, sterile ampoules/vials, and softgels; Çerkezköy-II (67,551 m²) for high-potency oncology, sterile liquids, animal health, API manufacturing, and the integrated biotechnology and R&D buildings; Kartepe (32,000 m²) for sterile liquids, ampoules, and cologne products; and Çerkezköy-IV, a 58,000 m² logistics center with 43,500-pallet capacity. Combined production capacity exceeds 620 million units annually.

The business model combines B2B product sales, contract manufacturing services, API exports, and licensing/co-development with international partners. Revenue is generated across multiple streams: sales of human pharmaceuticals, APIs, veterinary medicines, and consumer products (including cologne under Boğaziçi Kolonyaları). International reach is executed through ten wholly-owned Devatis subsidiaries in the US, Germany, UK, Switzerland, Netherlands, Canada, Mexico, Australia, and Serbia, supported by a network-based order-to-cash model (TraceLink MINT) in the US. Distribution extends to 80+ countries, with 1,863 product registrations across 86 countries including highly regulated markets. Customers include healthcare professionals, patients, and international pharmaceutical manufacturers using DEVA for contract manufacturing and API supply. Pricing is quote-based and not publicly disclosed; products are sold B2B via wholesalers, 3PLs, and direct distribution. The company is publicly listed on the Istanbul Stock Exchange under ticker DEVA, is majority-controlled by EastPharma Ltd., and reports under Chairman/CEO Philipp Haas.

Technology and R&D are anchored by the DEVARGE center, which employs 400+ researchers across pharmaceutical development, analytical development, API development, biotechnology, biosimilars, bioequivalence, and CMC documentation. Facilities operate under US FDA, EU GMP, ISO 9001, ISO 14001, ISO 45001, ISO 27001, and ISO 50001 certifications, with a UN registered-supplier status. Notable capabilities include Blow-Fill-Seal (BFS) sterile manufacturing, high-containment oncology production with isolator technology, and biosimilar development infrastructure. Workforce is 3,000+, with 219,660 hours of annual training and a Lost Time Injury Frequency Rate of 0.66.

Short descriptiontext

DEVA Holding A.Ş. is a vertically integrated Turkish pharmaceutical manufacturer founded in 1958 that produces APIs and finished dosage forms across 15 therapeutic areas, exporting through ten Devatis subsidiaries to 80+ countries with 1,863 product registrations in 86 markets.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersIstanbul
HQ citystring
Istanbul
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical manufacturing, active pharmaceutical ingredients, generic pharmaceuticals, contract manufacturing services, veterinary medicines
Industry3 codes
PRIMARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Pharmaceutical Manufacturing
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Pharmaceutical Products
TypeHardware Sales
Description

Manufacturing and sale of pharmaceutical products across 15 therapeutic areas including human pharmaceuticals, API production, veterinary medicines, and consumer health products. Products distributed through international network to 80+ countries.

deva.com.tr
2Contract Manufacturing Services
TypeProfessional Services
Description

High-quality contract manufacturing services provided to international partners in line with global quality standards including US FDA and EU GMP compliant facilities.

deva.com.tr
3Active Pharmaceutical Ingredients (API)
TypeHardware Sales
Description

Supply of active pharmaceutical ingredients developed in modern manufacturing facilities to pharmaceutical manufacturers worldwide, leveraging vertically integrated structure.

deva.com.tr
4Licensing and Co-development
TypeLicensing Royalties
Description

Through licensing agreements with international partners, expansion of product portfolio into new markets and development collaborations that create mutual value. Leveraging R&D capabilities for co-development of new pharmaceutical products.

deva.com.tr
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1Saba
Description

Healthcare brand with established presence and diverse product portfolio.

deva.com.tr
+3 more records
Core offering1 text field

DEVA Holding is a vertically integrated pharmaceutical manufacturer that develops, produces, and markets human pharmaceuticals across 15 therapeutic areas, active pharmaceutical ingredients (APIs), veterinary medicines, and consumer health products. The company operates four manufacturing facilities compliant with US FDA and EU GMP standards, conducts R&D through its DEVARGE center with 400+ researchers, and exports products to 60+ countries with 1,863 product registrations across 86 countries. Additional revenue lines include contract manufacturing services and licensing/co-development partnerships with international pharmaceutical firms.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 1,863 product registrations across 86 countries
+3 more records
Product overview1 text field

Deva Holding operates as a diversified pharmaceutical company with a portfolio of sub-brands including DEVA (core pharmaceutical products), Saba (consumer healthcare), Devatis (international operations), Vetas (animal health), and Boğaziçi Kolonyaları (consumer products). The company is organized around four main business segments: human pharmaceuticals with 15 therapeutic areas covering cardiopulmonary, cardiovascular, central nervous system, dermatology/immunology, musculoskeletal, oncology/hematology, respiratory, sensory organs, blood products, digestive/metabolism, genitourinary/sex hormones, systemic hormonal preparations, food supplements, and systemic anti-infectives; API (active pharmaceutical ingredients) manufacturing; veterinary pharmaceuticals; and other consumer products. DEVARGE serves as the integrated R&D center, while Devakademi provides internal learning and development programs.

Product and service5 records
1Human Pharmaceuticals
CategoryHuman Pharmaceuticals
2Active Pharmaceutical Ingredients (API)
CategoryActive Pharmaceutical Ingredients
3Veterinary Pharmaceuticals (Vetas)
CategoryVeterinary Pharmaceuticals
4Contract Manufacturing Services
CategoryContract Manufacturing
5Consumer Products (Boğaziçi Kolonyaları)
CategoryConsumer Products
Scale indicator15 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-04-21
Description

Devatis, the U.S. affiliate of Deva Holding, implemented TraceLink's Multienterprise Information Network Tower (MINT) to replace fragmented EDI integrations with a network-based order-to-cash model. Enables real-time transaction exchange with wholesalers, 3PL providers, and other trading partners through a single link. Reduces new partner onboarding timelines from months to as little as three days. Establishes data foundation for future AI agent-driven automation including price validation, order monitoring, shipment reconciliation, and anomaly detection.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

International operations managed through Devatis subsidiaries including Devatis Ltd, Devatis GmbH, Devatis Inc, Devatis AG, Devatis de Mexico S.DE RL. DE C.V., Devatis Pty Ltd, Devatis Canada Inc., Devatis d.o.o. Beograde, Devatis B.V., Devatis LLC, and Devatis UK Ltd. These entities manage commercial operations and expand presence across global pharmaceutical markets.

3Saba İlaç Sanayi ve Ticaret A.Ş.
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Saba brand operates under the DEVA ecosystem with an established presence in healthcare and a strong diverse product portfolio. Philipp Haas serves as Chairman of the Board of Saba İlaç Sanayi ve Ticaret A.Ş.

deva.com.tr
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Animal health portfolio under the DEVA ecosystem delivering reliable solutions supporting disease prevention and treatment. Vetas joined DEVA Holding in 2017.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Consumer product brand combining traditional cologne heritage with modern manufacturing, representing quality and trust.

Strategic tierCoreTypeOthers
Description

DEVA became a registered supplier of the United Nations, enabling supply of pharmaceutical products to UN procurement channels.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Extensive international distribution network bringing DEVA products to healthcare professionals and patients across different geographies. Operations in highly regulated markets including USA, Germany, UK, and Switzerland.

Recent move14 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Sandoz (Novartis)
TypeBroad incumbent
Description

Global generic and biosimilar powerhouse spun out of Novartis with a vertically integrated structure and strong biosimilar pipeline. Comparable to DEVA across generic finished doses, APIs, and biosimilars, with far deeper commercial reach in the US and EU.

TypeDirect peer
Description

Major Turkish generic pharmaceutical manufacturer with domestic manufacturing and broad therapeutic-area portfolio. Direct domestic competitor to DEVA in the Turkish generics market.

TypeDirect peer
Description

Indian vertically integrated generic and API manufacturer with strong US FDA footprint and global distribution. Closely comparable to DEVA in API + finished-dose model, export-heavy orientation, and regulated-market focus.

TypeDirect peer
Description

MENA-headquartered generic pharmaceutical manufacturer with strong US FDA approved manufacturing and broad therapeutic-area coverage. Comparable to DEVA in regulated-market generic finished doses, MENA + emerging market distribution, and FDA-compliant manufacturing.

TypeDirect peer
Description

Indian generic and API manufacturer with branded generics across multiple therapeutic areas and significant presence in regulated markets. Comparable to DEVA in finished-dose generics, API exports, and emerging-market leadership.

TypeBroad incumbent
Description

Global generics manufacturer formed from Mylan and Upjohn with broad therapeutic coverage and worldwide distribution. Comparable to DEVA as a finished-dose generics competitor with established presence across both emerging and regulated markets.

TypeBroad incumbent
Description

World's largest generic pharmaceutical manufacturer with a vertically integrated API-to-finished-dose model and global distribution across 60+ markets. Directly comparable to DEVA in generic finished doses and APIs, though at materially larger scale and broader therapeutic coverage.

TypeDirect peer
Description

Turkey's largest domestic pharmaceutical company, offering branded generics and consumer health products with manufacturing and R&D in Turkey. Closest direct domestic peer to DEVA, competing in the same Turkish market and overlapping therapeutic areas.

TypeRegional player
Description

Diversified Turkish conglomerate with consumer-health and pharmaceutical operations serving primarily the Turkish and regional markets. Comparable as a Turkish pharmaceutical operator with adjacent consumer-health exposure to DEVA's Saba and Boğaziçi Kolonyaları businesses.

TypeDirect peer
Description

European-headquartered generic pharmaceutical manufacturer with vertically integrated operations and strong presence in CEE and Western Europe. Directly comparable to DEVA in generic finished doses and EU regulatory footprint; Philipp Haas previously consulted for its predecessor Slovakopharma.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries15 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Deva

Pharmaceutical Manufacturingdeva.com.tr

DEVA Holding A.Ş. is a vertically integrated Turkish pharmaceutical manufacturer founded in 1958 that produces APIs and finished dosage forms across 15 therapeutic areas, exporting through ten Devatis subsidiaries to 80+ countries with 1,863 product registrations in 86 markets.

What Deva does

DEVA Holding A.Ş. is a vertically integrated Turkish pharmaceutical manufacturer founded in 1958 and headquartered in Istanbul. The company produces both active pharmaceutical ingredients (APIs) and finished dosage forms across 15 therapeutic areas, including cardiology, oncology, respiratory, hematology, dermatology/immunology, central nervous system, and musculoskeletal segments. Manufacturing is concentrated at four Turkish facilities: Çerkezköy-I (52,000 m²) for liquids, semi-solids, cephalosporins, penicillins, hormones, inhalation products, sterile ampoules/vials, and softgels; Çerkezköy-II (67,551 m²) for high-potency oncology, sterile liquids, animal health, API manufacturing, and the integrated biotechnology and R&D buildings; Kartepe (32,000 m²) for sterile liquids, ampoules, and cologne products; and Çerkezköy-IV, a 58,000 m² logistics center with 43,500-pallet capacity. Combined production capacity exceeds 620 million units annually.

The business model combines B2B product sales, contract manufacturing services, API exports, and licensing/co-development with international partners. Revenue is generated across multiple streams: sales of human pharmaceuticals, APIs, veterinary medicines, and consumer products (including cologne under Boğaziçi Kolonyaları). International reach is executed through ten wholly-owned Devatis subsidiaries in the US, Germany, UK, Switzerland, Netherlands, Canada, Mexico, Australia, and Serbia, supported by a network-based order-to-cash model (TraceLink MINT) in the US. Distribution extends to 80+ countries, with 1,863 product registrations across 86 countries including highly regulated markets. Customers include healthcare professionals, patients, and international pharmaceutical manufacturers using DEVA for contract manufacturing and API supply. Pricing is quote-based and not publicly disclosed; products are sold B2B via wholesalers, 3PLs, and direct distribution. The company is publicly listed on the Istanbul Stock Exchange under ticker DEVA, is majority-controlled by EastPharma Ltd., and reports under Chairman/CEO Philipp Haas.

Technology and R&D are anchored by the DEVARGE center, which employs 400+ researchers across pharmaceutical development, analytical development, API development, biotechnology, biosimilars, bioequivalence, and CMC documentation. Facilities operate under US FDA, EU GMP, ISO 9001, ISO 14001, ISO 45001, ISO 27001, and ISO 50001 certifications, with a UN registered-supplier status. Notable capabilities include Blow-Fill-Seal (BFS) sterile manufacturing, high-containment oncology production with isolator technology, and biosimilar development infrastructure. Workforce is 3,000+, with 219,660 hours of annual training and a Lost Time Injury Frequency Rate of 0.66.

Deva firmographics

Firmographics
Name
Deva
Legal name
DEVA HOLDİNG ANONİM ŞİRKETİ
Website
https://deva.com.tr
Company type
Public
Founded year
1958
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
DEVA Holding A.Ş. is a vertically integrated Turkish pharmaceutical manufacturer founded in 1958 that produces APIs and finished dosage forms across 15 therapeutic areas, exporting through ten Devatis subsidiaries to 80+ countries with 1,863 product registrations in 86 markets.
Ownership category
akta.pro rank

Deva industry classification

Industry
Product category
Pharmaceutical Manufacturing
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
SIC
Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Pharmaceutical manufacturing
  • Active pharmaceutical ingredients
  • Generic pharmaceuticals
  • Contract manufacturing services
  • Veterinary medicines

Where Deva is headquartered

Location

Headquarters

HQ city
Istanbul

Offices5 records

Markets served

Deva business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. Pharmaceutical Products: Manufacturing and sale of pharmaceutical products across 15 therapeutic areas including human pharmaceuticals, API production, veterinary medicines, and consumer health products. Products distributed through international network to 80+ countries.
  2. Contract Manufacturing Services: High-quality contract manufacturing services provided to international partners in line with global quality standards including US FDA and EU GMP compliant facilities.
  3. Active Pharmaceutical Ingredients (API): Supply of active pharmaceutical ingredients developed in modern manufacturing facilities to pharmaceutical manufacturers worldwide, leveraging vertically integrated structure.
  4. Licensing and Co-development: Through licensing agreements with international partners, expansion of product portfolio into new markets and development collaborations that create mutual value. Leveraging R&D capabilities for co-development of new pharmaceutical products.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels5 records

Deva product offering

Product offering

Core offering

DEVA Holding is a vertically integrated pharmaceutical manufacturer that develops, produces, and markets human pharmaceuticals across 15 therapeutic areas, active pharmaceutical ingredients (APIs), veterinary medicines, and consumer health products. The company operates four manufacturing facilities compliant with US FDA and EU GMP standards, conducts R&D through its DEVARGE center with 400+ researchers, and exports products to 60+ countries with 1,863 product registrations across 86 countries. Additional revenue lines include contract manufacturing services and licensing/co-development partnerships with international pharmaceutical firms.

Product overview

Deva Holding operates as a diversified pharmaceutical company with a portfolio of sub-brands including DEVA (core pharmaceutical products), Saba (consumer healthcare), Devatis (international operations), Vetas (animal health), and Boğaziçi Kolonyaları (consumer products). The company is organized around four main business segments: human pharmaceuticals with 15 therapeutic areas covering cardiopulmonary, cardiovascular, central nervous system, dermatology/immunology, musculoskeletal, oncology/hematology, respiratory, sensory organs, blood products, digestive/metabolism, genitourinary/sex hormones, systemic hormonal preparations, food supplements, and systemic anti-infectives; API (active pharmaceutical ingredients) manufacturing; veterinary pharmaceuticals; and other consumer products. DEVARGE serves as the integrated R&D center, while Devakademi provides internal learning and development programs.

Differentiator

Problem solved

Functional benefit

Brands

  • Saba: Healthcare brand with established presence and diverse product portfolio.
  • Devatis
  • Vetas
  • Boğaziçi Kolonyaları

Products and services

  • Human Pharmaceuticals
  • Active Pharmaceutical Ingredients (API)
  • Veterinary Pharmaceuticals (Vetas)
  • Contract Manufacturing Services
  • Consumer Products (Boğaziçi Kolonyaları)

Quantifiable outcome

  • 1,863 product registrations across 86 countries
  • +3 more outcomes

Companies that use Deva

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Deva technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

Feature5 records

Deva partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • TraceLinkcoreTechnology or Integration · 21 April 2026Devatis, the U.S. affiliate of Deva Holding, implemented TraceLink's Multienterprise Information Network Tower (MINT) to replace fragmented EDI integrations with a network-based order-to-cash model. Enables real-time transaction exchange with wholesalers, 3PL providers, and other trading partners through a single link. Reduces new partner onboarding timelines from months to as little as three days. Establishes data foundation for future AI agent-driven automation including price validation, order monitoring, shipment reconciliation, and anomaly detection.
  • Devatis SubsidiariescoreChannel Partner/ Reseller/ DistributorInternational operations managed through Devatis subsidiaries including Devatis Ltd, Devatis GmbH, Devatis Inc, Devatis AG, Devatis de Mexico S.DE RL. DE C.V., Devatis Pty Ltd, Devatis Canada Inc., Devatis d.o.o. Beograde, Devatis B.V., Devatis LLC, and Devatis UK Ltd. These entities manage commercial operations and expand presence across global pharmaceutical markets.
  • Saba İlaç Sanayi ve Ticaret A.Ş.coreStrategic or Co-development PartnerSaba brand operates under the DEVA ecosystem with an established presence in healthcare and a strong diverse product portfolio. Philipp Haas serves as Chairman of the Board of Saba İlaç Sanayi ve Ticaret A.Ş.
  • VetascoreChannel Partner/ Reseller/ DistributorAnimal health portfolio under the DEVA ecosystem delivering reliable solutions supporting disease prevention and treatment. Vetas joined DEVA Holding in 2017.
  • Boğaziçi KolonyalarıminorChannel Partner/ Reseller/ DistributorConsumer product brand combining traditional cologne heritage with modern manufacturing, representing quality and trust.
  • United NationscoreOthersDEVA became a registered supplier of the United Nations, enabling supply of pharmaceutical products to UN procurement channels.
  • International Distribution PartnerscoreChannel Partner/ Reseller/ DistributorExtensive international distribution network bringing DEVA products to healthcare professionals and patients across different geographies. Operations in highly regulated markets including USA, Germany, UK, and Switzerland.

Scale indicators15 records

Recent moves14 records

Expansion highlights6 records

Deva competitors and assessment

Company assessment

Broad incumbents

  • Sandoz (Novartis): Global generic and biosimilar powerhouse spun out of Novartis with a vertically integrated structure and strong biosimilar pipeline. Comparable to DEVA across generic finished doses, APIs, and biosimilars, with far deeper commercial reach in the US and EU.
  • Viatris: Global generics manufacturer formed from Mylan and Upjohn with broad therapeutic coverage and worldwide distribution. Comparable to DEVA as a finished-dose generics competitor with established presence across both emerging and regulated markets.
  • Teva Pharmaceutical Industries: World's largest generic pharmaceutical manufacturer with a vertically integrated API-to-finished-dose model and global distribution across 60+ markets. Directly comparable to DEVA in generic finished doses and APIs, though at materially larger scale and broader therapeutic coverage.

Direct peers

  • Bilim Pharmaceuticals: Major Turkish generic pharmaceutical manufacturer with domestic manufacturing and broad therapeutic-area portfolio. Direct domestic competitor to DEVA in the Turkish generics market.
  • Aurobindo Pharma: Indian vertically integrated generic and API manufacturer with strong US FDA footprint and global distribution. Closely comparable to DEVA in API + finished-dose model, export-heavy orientation, and regulated-market focus.
  • Hikma Pharmaceuticals: MENA-headquartered generic pharmaceutical manufacturer with strong US FDA approved manufacturing and broad therapeutic-area coverage. Comparable to DEVA in regulated-market generic finished doses, MENA + emerging market distribution, and FDA-compliant manufacturing.
  • Dr. Reddy's Laboratories: Indian generic and API manufacturer with branded generics across multiple therapeutic areas and significant presence in regulated markets. Comparable to DEVA in finished-dose generics, API exports, and emerging-market leadership.
  • Abdi İbrahim: Turkey's largest domestic pharmaceutical company, offering branded generics and consumer health products with manufacturing and R&D in Turkey. Closest direct domestic peer to DEVA, competing in the same Turkish market and overlapping therapeutic areas.
  • Zentiva: European-headquartered generic pharmaceutical manufacturer with vertically integrated operations and strong presence in CEE and Western Europe. Directly comparable to DEVA in generic finished doses and EU regulatory footprint; Philipp Haas previously consulted for its predecessor Slovakopharma.

Regional players

  • Eczacıbaşı Group (pharmaceutical operations): Diversified Turkish conglomerate with consumer-health and pharmaceutical operations serving primarily the Turkish and regional markets. Comparable as a Turkish pharmaceutical operator with adjacent consumer-health exposure to DEVA's Saba and Boğaziçi Kolonyaları businesses.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Deva social profiles

Digital presence

Deva compliance and trust

Trust signal

Compliance5 records

Deva financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Deva leadership team

Management profile

Number of profiles

Profiles6 records

Deva subsidiaries and ownership

Company hierarchy

Subsidiaries15 records

Deva funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Deva M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Deva

What does Deva do?

DEVA Holding is a vertically integrated pharmaceutical manufacturer that develops, produces, and markets human pharmaceuticals across 15 therapeutic areas, active pharmaceutical ingredients (APIs), veterinary medicines, and consumer health products. The company operates four manufacturing facilities compliant with US FDA and EU GMP standards, conducts R&D through its DEVARGE center with 400+ researchers, and exports products to 60+ countries with 1,863 product registrations across 86 countries. Additional revenue lines include contract manufacturing services and licensing/co-development partnerships with international pharmaceutical firms.

Is Deva a public or private company?

Deva is a public company. It is classified as public and is currently operating.

When was Deva founded?

Deva was founded in 1958. It employs 1,001 to 5,000 people.

Where is Deva based?

Deva is headquartered in Istanbul.

How does Deva make money?

Four revenue lines are on record. Pharmaceutical Products are the primary driver. The others are contract Manufacturing Services, active Pharmaceutical Ingredients (API) and licensing and Co-development.

Who are Deva's main competitors?

Broad incumbents on record are Sandoz (Novartis), Viatris and Teva Pharmaceutical Industries. Direct peers are Bilim Pharmaceuticals, Aurobindo Pharma, Hikma Pharmaceuticals, Dr. Reddy's Laboratories, Abdi İbrahim and Zentiva. Eczacıbaşı Group (pharmaceutical operations) is listed as a regional player.

Does Deva have an API?

No public API is recorded for Deva.

What industry is Deva in?

Deva's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAGAHAL, GMP Scale-Up, Tech Transfer & Process Validation (PPQ), with a secondary code of HLAGAHAM, Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TipranksDeva Holding Shares Enter Call Auction After Circuit Breaker HaltTrading in Deva Holding A.S. shares was temporarily halted after an equity-based circuit breaker was triggered, moving the stock into a single-price call auction phase. The exchange plans to resume transactions at 13:16:14 following the completion of this auction to stabilize price volatility.Stock TitanAspire Biopharma Holds 16 Partner Meetings at CPHI FrankfurtAspire Biopharma held 16 face-to-face meetings at CPHI Frankfurt with pharmaceutical companies, including Bayer and Deva Holdings, to discuss licensing its sublingual high-dose aspirin. The product's investigational study showed higher and faster plasma concentrations of acetylsalicylic acid than chewed tablets, supporting its potential for acute myocardial infarction treatment.MintJSW group appoints Gaurav Sachdeva as CEO of e-commerce venture JSW One Platform | Company Business NewsJSW group appointed Gaurav Sachdeva as CEO of its e-commerce venture JSW One Platforms. Sachdeva previously led venture capital investments at JSW Ventures. The platform aims to offer a one-stop solution for MSMEs in steel, cement, and paints, with an ESOP policy planned.GlobeNewswireAdvance Notice: Reviewed Financial Statement's announcement for the period 30 June 2018EastPharma will release its reviewed financial statements for the period ended 30 June 2018 and a review of its subsidiary DEVA Holding's statements on 13 August 2018. A management-hosted conference call to review the financial performance will be held on 14 August 2018 at 11:00am London time.GlobeNewswireAdvance Notice: Sales Update Announcement for the period 31 March 2014EastPharma will announce its Q1 2014 sales performance and review of subsidiary DEVA Holding's financial statements on 12 May 2014. A management-hosted conference call will be held on 13 May 2014 at 4:00pm London time, with dial-in details provided.GlobeNewswireAdvance Notice: Audited Financial Statements' Announcement for The Year Ended 31 December 2013EastPharma will announce its 2013 audited financial statements and those of its subsidiary DEVA Holding on 10 March 2014. A management-hosted conference call to review 2013 performance is scheduled for 20 March 2014 at 4:00pm London time.GlobeNewswireUPDATE: Advance Notice: Sales Update Announcement for the period 31 March 2013EastPharma announced its Q1 2013 sales performance and a review of its subsidiary DEVA Holding's financial statements on 16 May 2013. A conference call to review the sales performance will be held on 17 May 2013 at 4:00pm London time.